ID: ALA4560325

Max Phase: Preclinical

Molecular Formula: C17H16FN

Molecular Weight: 253.32

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  C#CCN(C)Cc1ccc(-c2ccc(F)cc2)cc1

Standard InChI:  InChI=1S/C17H16FN/c1-3-12-19(2)13-14-4-6-15(7-5-14)16-8-10-17(18)11-9-16/h1,4-11H,12-13H2,2H3

Standard InChI Key:  UMAULUSJIGOJJQ-UHFFFAOYSA-N

Associated Targets(Human)

Pyrroline-5-carboxylate reductase 1, mitochondrial 71 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 253.32Molecular Weight (Monoisotopic): 253.1267AlogP: 3.56#Rotatable Bonds: 4
Polar Surface Area: 3.24Molecular Species: NEUTRALHBA: 1HBD: 0
#RO5 Violations: 0HBA (Lipinski): 1HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 7.96CX LogP: 3.93CX LogD: 3.27
Aromatic Rings: 2Heavy Atoms: 19QED Weighted: 0.75Np Likeness Score: -1.36

References

1. Milne K, Sun J, Zaal EA, Mowat J, Celie PHN, Fish A, Berkers CR, Forlani G, Loayza-Puch F, Jamieson C, Agami R..  (2019)  A fragment-like approach to PYCR1 inhibition.,  29  (18): [PMID:31362921] [10.1016/j.bmcl.2019.07.047]

Source